Tetrahydrobiopterin improves microcirculation in experimental sepsis
Tristan C Dumbarton1, Alexander Maxan2, Nizam Farah2
1Departments of Anesthesiology, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS, Canada.
Clinical Hemorheology and Microcirculation
|June 10, 2017
Summary
Tetrahydrobiopterin (BH4) improved intestinal capillary density and reduced inflammation in rat sepsis models. BH4 shows potential as a novel treatment for sepsis and septic shock.
Area of Science:
- Sepsis research
- Vascular biology
- Pharmacology
Background:
- Tetrahydrobiopterin (BH4) is a crucial cofactor for endothelial enzymes.
- Endothelial dysfunction is a hallmark of sepsis.
Purpose of the Study:
- To investigate BH4's effects on capillary density and inflammation in the intestinal microcirculation of septic rats.
- To test the hypothesis that BH4 improves microcirculatory function during sepsis.
Main Methods:
- Randomized controlled trial in two validated rat sepsis models: fecal peritonitis and endotoxemia (LPS).
- BH4 (60 μg/kg) administration compared to controls and untreated septic groups.
- Assessment of leukocyte-endothelial adhesion and functional capillary density.
Main Results:
- BH4 significantly reduced leukocyte-endothelial adhesion in both peritonitis (55%) and endotoxemia (58%) models.
- BH4 improved intestinal functional capillary density in the endotoxemia model (141.3 vs. 106.7 μm/cm²).
- No significant differences in macrohemodynamic parameters were observed.
Conclusions:
- BH4 demonstrates efficacy in improving capillary density and reducing inflammation in experimental sepsis.
- BH4 may offer a novel therapeutic strategy for sepsis and septic shock.
- Further research, including dose-finding studies and clinical trials, is recommended.
